The estimated Net Worth of Vassiliki Economides is at least $163 millier dollars as of 15 May 2024. Ms. Economides owns over 13,749 units of Kezar Life Sciences Inc stock worth over $152,213 and over the last 6 years she sold KZR stock worth over $10,312. In addition, she makes $0 as Senior Vice President - Strategy and External Affairs at Kezar Life Sciences Inc.
Vassiliki has made over 7 trades of the Kezar Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 13,749 units of KZR stock worth $10,312 on 15 May 2024.
The largest trade she's ever made was selling 13,749 units of Kezar Life Sciences Inc stock on 15 May 2024 worth over $10,312. On average, Vassiliki trades about 2,271 units every 121 days since 2019. As of 15 May 2024 she still owns at least 262,437 units of Kezar Life Sciences Inc stock.
You can see the complete history of Ms. Economides stock trades at the bottom of the page.
Vassiliki Celia Economides serves as Senior Vice President - Strategy and External Affairs of the Company. Ms. Economides has nearly 20 years of experience in the life sciences and biotech industries, spanning finance, corporate strategy, communications, patient advocacy, clinical, medical and government affairs. Prior to joining Kezar, Ms. Economides served as Vice President, Corporate Affairs at Aurinia Pharmaceuticals, Inc. from July 2016 to March 2019, where she led the company’s investor relations, corporate communications, and patient advocacy efforts, establishing relationships and alliances with key advocacy groups across the company’s therapeutic focus. Previously, Ms. Economides served as Director, Global Medical Affairs and Director, Clinical Operations at BioMarin Pharmaceutical, Inc. after the Company’s acquisition of Prosensa where she led IR and corporate communications. Earlier in her career, she led investor relations and program development at the Biotechnology Innovation Organization (BIO) and worked at a healthcare focused hedge fund and in financial services focusing on the biotech sector.
Vassiliki Economides is 40, she's been the Senior Vice President - Strategy and External Affairs of Kezar Life Sciences Inc since 2019. There are 14 older and no younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.
Vassiliki's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... et Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: